Showing 6621-6630 of 8237 results for "".
- New Survey Reveals Negative Impact of Psoriasis on Mental Healthhttps://practicaldermatology.com/news/new-survey-reveals-negative-impact-of-psoriasis-on-mental-health/2461159/Arcutis Biotherapeutics, Inc. recently shared findings from the Skin Insights: Uncovering Psoriasis Survey, a national survey of 507 adults 18+ diagnosed with plaque psoriasis who are on topical treatments. The online survey was conducted by The Harris Poll and was designed to reveal insight
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Country Music Artist Ashley Barron Named National Scleroderma Foundation’s Celebrity Ambassadorhttps://practicaldermatology.com/news/country-music-artist-ashley-barron-named-national-scleroderma-foundations-celebrity-ambassador/2461155/Country music artist Ashley Barron is the National Scleroderma Foundation’s official Celebrity Ambassador. Barron was diagnosed with scleroderma at age five. At that time, her family had never heard of the disease. Now as Celebrity Ambassador, Barron is working to represent
- Arcutis Completes Enrollment in Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-phase-3-trial-of-topical-roflumilast-foam-in-scalp-and-body-psoriasis/2461153/Enrollment in Arcutis’ ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis is complete, the company reported. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (
- Bill Scott Named President of Endymed's US Subsidiaryhttps://practicaldermatology.com/news/bill-scott-named-president-of-endymeds-us-subsidiary/2461151/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was